Ensysce Biosciences Current Valuation vs. Shares Owned By Institutions
| ENSC Stock | USD 0.48 0.05 11.63% |
For Ensysce Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ensysce Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ensysce Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ensysce Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ensysce Biosciences over time as well as its relative position and ranking within its peers.
Ensysce |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.94) | Revenue Per Share 0.274 | Quarterly Revenue Growth (0.63) | Return On Assets (1.32) | Return On Equity (4.28) |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Ensysce Biosciences Shares Owned By Institutions vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Ensysce Biosciences's current stock value. Our valuation model uses many indicators to compare Ensysce Biosciences value to that of its competitors to determine the firm's financial worth. Ensysce Biosciences is rated below average in current valuation category among its peers. It is rated below average in shares owned by institutions category among its peers . The ratio of Current Valuation to Shares Owned By Institutions for Ensysce Biosciences is about 251,825 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ensysce Biosciences' earnings, one of the primary drivers of an investment's value.Ensysce Current Valuation vs. Competition
Ensysce Biosciences is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 571.81 Million. Ensysce Biosciences maintains roughly 5.61 Million in current valuation contributing less than 1% to equities under Health Care industry.
Ensysce Shares Owned By Institutions vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Ensysce Biosciences |
| = | 5.61 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Ensysce Biosciences |
| = | 22.26 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Ensysce Shares Owned By Institutions Comparison
Ensysce Biosciences is currently under evaluation in shares owned by institutions category among its peers.
Ensysce Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Ensysce Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Ensysce Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Ensysce Biosciences' change in net profit over the period of time. It can combine multiple indicators of Ensysce Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Interest Income | 98.6 K | 93.6 K | |
| Operating Income | -10.7 M | -11.3 M | |
| Income Before Tax | -10.6 M | -11.2 M | |
| Net Loss | -22.6 M | -21.4 M | |
| Net Loss | -10.6 M | -11.2 M | |
| Net Loss | -12.6 M | -13.2 M | |
| Non Operating Income Net Other | 6.8 M | 5.1 M | |
| Total Other Income Expense Net | 91.9 K | 96.5 K | |
| Income Tax Expense | (264.00) | (250.80) | |
| Net Interest Income | -80 K | -84 K | |
| Change To Netincome | 23.3 M | 24.4 M | |
| Net Loss | (4.69) | (4.92) | |
| Income Quality | 1.01 | 0.96 | |
| Net Income Per E B T | 1.00 | 1.27 |
Ensysce Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Ensysce Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Ensysce Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Ensysce Biosciences' important profitability drivers and their relationship over time.
Use Ensysce Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ensysce Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ensysce Biosciences will appreciate offsetting losses from the drop in the long position's value.Ensysce Biosciences Pair Trading
Ensysce Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Ensysce Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ensysce Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ensysce Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ensysce Biosciences to buy it.
The correlation of Ensysce Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ensysce Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ensysce Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ensysce Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Ensysce Biosciences position
In addition to having Ensysce Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gold ETFs Thematic Idea Now
Gold ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Gold ETFs theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gold ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
To fully project Ensysce Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Ensysce Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Ensysce Biosciences' income statement, its balance sheet, and the statement of cash flows.